COMP <GO>
AUPH vs JNJ // OPERATING MARGIN
Aurinia Pharmaceuticals Inc (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: AUPH 7
— JNJ 5
▲ OPERATING MARGIN LEADER: AUPH
LAST: $16.65 (-3.25%) • MKT CAP: $2.29B
operating-margins
37.10%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
operating-margins
34.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AUPH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 67.90% | +20.60 | AUPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 25.50% | -9.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.1x | 18.5x | +2.60 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 5.92% | 2.97% | +2.95 | AUPH | /fcf-yield <GO> |
| Operating Margin ACTIVE | 37.10% | 34.70% | +2.40 | AUPH | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.50% | +39.50 | AUPH | /net-margins <GO> |
| Revenue Growth (YoY) | 20.40% | 6.00% | +14.40 | AUPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.33 | 5.59 | +2.74 | AUPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 62.1 | -4.80 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.7x | 23.0x | -16.30 | AUPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.29B | $662.49B | -$660.20B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AUPH REV | JNJ REV | AUPH GROSS % | JNJ GROSS % | AUPH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $283.1M | $94.19B | 88.5% | 67.9% | $135.7M | $19.70B |
| FY 2024 | $235.1M | $88.82B | 88.0% | 69.1% | $44.4M | $19.84B |
| FY 2023 | $175.5M | $85.16B | — | — | -$33.5M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
JNJ // BETA 1.08